Switch theme
Sign up to access all valuation multiples
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
1983
186
LTM Revenue $5.6M
LTM EBITDA -$212M
$641M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celldex Therapeutics has a last 12-month revenue (LTM) of $5.6M and a last 12-month EBITDA of -$212M.
In the most recent fiscal year, Celldex Therapeutics achieved revenue of $7.0M and an EBITDA of -$192M.
Celldex Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celldex Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.6M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Profit | $5.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$212M | XXX | -$192M | XXX | XXX | XXX |
| EBITDA Margin | -3794% | XXX | -2734% | XXX | XXX | XXX |
| EBIT | -$218M | XXX | -$195M | XXX | XXX | XXX |
| EBIT Margin | -3896% | XXX | -2779% | XXX | XXX | XXX |
| Net Profit | -$189M | XXX | -$158M | XXX | XXX | XXX |
| Net Margin | -3373% | XXX | -2249% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Celldex Therapeutics's stock price is $20.
Celldex Therapeutics has current market cap of $1.3B, and EV of $641M.
See Celldex Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $641M | $1.3B | XXX | XXX | XXX | XXX | $-2.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Celldex Therapeutics has market cap of $1.3B and EV of $641M.
Celldex Therapeutics's trades at 91.4x EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Celldex Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celldex Therapeutics has a P/E ratio of -6.9x.
See valuation multiples for Celldex Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $641M | XXX | $641M | XXX | XXX | XXX |
| EV/Revenue | 114.7x | XXX | 91.4x | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -2.9x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 114.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.9x | XXX | -8.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCelldex Therapeutics's last 12 month revenue growth is -43%
Celldex Therapeutics's revenue per employee in the last FY averaged $38K, while opex per employee averaged $1.1M for the same period.
Celldex Therapeutics's rule of 40 is -2063% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celldex Therapeutics's rule of X is -3901% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Celldex Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -43% | XXX | -39% | XXX | XXX | XXX |
| EBITDA Margin | -3794% | XXX | -2734% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2063% | XXX | -2777% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3901% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2330% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2879% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celldex Therapeutics acquired XXX companies to date.
Last acquisition by Celldex Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Celldex Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Celldex Therapeutics founded? | Celldex Therapeutics was founded in 1983. |
| Where is Celldex Therapeutics headquartered? | Celldex Therapeutics is headquartered in United States of America. |
| How many employees does Celldex Therapeutics have? | As of today, Celldex Therapeutics has 186 employees. |
| Who is the CEO of Celldex Therapeutics? | Celldex Therapeutics's CEO is Mr. Anthony S. Marucci. |
| Is Celldex Therapeutics publicy listed? | Yes, Celldex Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Celldex Therapeutics? | Celldex Therapeutics trades under CLDX ticker. |
| When did Celldex Therapeutics go public? | Celldex Therapeutics went public in 1990. |
| Who are competitors of Celldex Therapeutics? | Similar companies to Celldex Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celldex Therapeutics? | Celldex Therapeutics's current market cap is $1.3B |
| What is the current revenue of Celldex Therapeutics? | Celldex Therapeutics's last 12 months revenue is $5.6M. |
| What is the current revenue growth of Celldex Therapeutics? | Celldex Therapeutics revenue growth (NTM/LTM) is -43%. |
| What is the current EV/Revenue multiple of Celldex Therapeutics? | Current revenue multiple of Celldex Therapeutics is 114.7x. |
| Is Celldex Therapeutics profitable? | Yes, Celldex Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Celldex Therapeutics? | Celldex Therapeutics's last 12 months EBITDA is -$212M. |
| What is Celldex Therapeutics's EBITDA margin? | Celldex Therapeutics's last 12 months EBITDA margin is -3794%. |
| What is the current EV/EBITDA multiple of Celldex Therapeutics? | Current EBITDA multiple of Celldex Therapeutics is -3.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
